Table of contents
January 2007 Vol 6 No 1
In this issue
p1 | doi:10.1038/nrd2228
Editorial: Five years on...and four challenges for the pharmaceutical industry
p3 | doi:10.1038/nrd2229
News and Analysis
Pharma faces major challenges after a year of failures and heated battles | PDF (261 KB)
p5 | doi:10.1038/nrd2230
News Feature: A call to arms | PDF (278 KB)
p8 | doi:10.1038/nrd2225
News in Brief
Patent watch
Obituary
Francis Patrick Tally, M.D. | PDF (129 KB)
p18 | doi:10.1038/nrd2233
From the analyst's couch
The antibacterial drugs market | PDF (177 KB)
p19 | doi:10.1038/nrd2226
Fresh from the Pipeline
Vorinostat | PDF (194 KB)
p21 | doi:10.1038/nrd2227
Research Highlights
Antibacterial drugs: Riboswitching off bacterial growth | PDF (148 KB)
p23 | doi:10.1038/nrd2235
Analgesia: Fast-track to pain relief | PDF (168 KB)
p24 | doi:10.1038/nrd2236
Pain: Pinning down neuropathic pain | PDF (308 KB)
p24 | doi:10.1038/nrd2237
Anticancer drugs: Inhibiting the inhibitors | PDF (234 KB)
p25 | doi:10.1038/nrd2239
Alzheimer's disease: Choice cuts? | PDF (179 KB)
p26 | doi:10.1038/nrd2234
In brief
Stem cells | Nanotechnology | Parkinson's Disease | PDF (179 KB)
p26 | doi:10.1038/nrd2238
Foreword
Focus on: Antibacterials
Reviews
Drugs for bad bugs: confronting the challenges of antibacterial discovery
David J. Payne, Michael N. Gwynn, David J. Holmes & David L. Pompliano
p29 | doi:10.1038/nrd2201
Genomics promised to revitalize the search for new antibiotics but still no new drug class against a novel target has materialized. Payne and colleagues describe the frustrations of their genomics efforts at GlaxoSmithKline and how this changed their approach to antibacterial R&D.
Multi-targeting by monotherapeutic antibacterials
Lynn L Silver
p41 | doi:10.1038/nrd2202
The debate about whether truly novel, tractable targets exist for antibacterial drug discovery continues. Meanwhile, as Lynn Silver discusses, efforts are focused on learning from the 'good old targets' to improve current antibiotic classes and develop antibacterial strategies for the future.
Waltzing transporters and 'the dance macabre' between humans and bacteria
Olga Lomovskaya, Helen I. Zgurskaya, Maxim Totrov & William J. Watkins
p56 | doi:10.1038/nrd2200
An attractive strategy to render drug-resistant bacteria susceptible to antibiotics is to inhibit the bacterial efflux pump. Lomovskaya and colleagues review the available structural data on the most effective class of bacterial efflux pumps and discuss current development of small-molecule efflux inhibitors.
Reviews
Inhaling medicines: delivering drugs to the body through the lungs
John S. Patton & Peter R. Byron
p67 | doi:10.1038/nrd2153
The potential for using the lungs as a gateway for delivering drugs to the systemic circulation is attracting increasing attention. Here, Patton and Byron review current issues in the formulation and systemic delivery of small molecules and macromolecules as inhaled therapeutics.
Biologic therapies in rheumatology: lessons learned, future directions
Vibeke Strand, Robert Kimberly & John D. Isaacs
p75 | doi:10.1038/nrd2196
Clinical use of biologic therapies for rheumatology has revealed that efficacy, toxicity and pharmacodynamic effects can deviate from those predicted. In this review, Issacs and colleagues summarize lessons gleaned from practical experience and discuss how these can inform future development of new biologic therapies.
